Clear Search

Showing 16 results for “Anifrolumab”.

May 2022

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Ann Rheum Dis. 2022; 0:1–11. doi: 10.1136/annrheumdis-2021-221425

IFN-I signalling plays a key role in SLE pathogenesis, and anifrolumab has demonstrated inhibitory effects on IFN-I signalling in patients with SLE. Vital, et al. characterised efficacy and safety of anifrolumab in patients with moderate-to-severe SLE based on interferon gene signature, demographic and clinical subgroups using data pooled from the Phase III TULIP-1 and -2 trials.

more…

March 2022

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Ann Rheum Dis. 2022;81(4):496–506 doi: 10.1136/annrheumdis-2021-221478

Despite not meeting the primary endpoint, this Phase II trial of anifrolumab in patients with active lupus nephritis (LN) demonstrates that anifrolumab IR is associated with numerical improvements over placebo across endpoints – including complete renal response – in patients with active LN.

more…

October 2021